Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination
- 8 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (10) , 2079-2085
Abstract
INTRODUCTION: Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory bowel disease (IBD). Although the 2-dose Heplisav-B vaccine has proven effective, more than 20% of patients with IBD do not seroconvert. We prospectively evaluated the effectiveness of a third Heplisav-B dose in patients with IBD lacking HBV immunity despite 2-dose vaccination. METHODS: Adults with IBD who had received 2-dose Heplisav-B vaccination between 2018 and 2023 were identified. Seroconversion was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L measured at ≥4 weeks after vaccination. Patients who did not seroconvert were prospectively offered a third Heplisav-B dose, followed by repeat HBsAb measurement. Demographic, clinical, medication, and vaccination data were compared between those who did and did not seroconvert. RESULTS: Of 192 patients identified, 71.9% (138/192) seroconverted after 2-dose Heplisav-B vaccination. The 54 patients (28.1%) who did not seroconvert were more likely to be male, have diabetes, chronic kidney disease, or elevated Charlson Comorbidity Index. Of the 54 patients, 30 (55.6%) elected to receive a third Heplisav-B dose, with 56.7% (17/30) achieving seroconversion (median HBsAb titer 376 IU/L, IQR 47–1,000 IU/L) despite a median intervaccination time of 416 days (IQR 90.8–667.8). No differences were noted between patients who did vs did not seroconvert after third-dose vaccination. DISCUSSION: In patients with IBD lacking HBV immunity despite 2-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary 2-dose vaccination.Keywords
This publication has 21 references indexed in Scilit:
- Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapyVaccine, 2023
- Measuring of Postvaccination Hepatitis B Titers in Patients With Inflammatory Bowel Disease: Thoughts for Further InvestigationClinical Gastroenterology and Hepatology, 2023
- Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver DiseaseDigestive Diseases and Sciences, 2020
- Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With CirrhosisClinical Gastroenterology and Hepatology, 2019
- Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2019
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- ACG Clinical Guideline: Preventive Care in Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2017
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2014
- Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney diseaseVaccine, 2013
- Patients with Inflammatory Bowel Disease Have a Lower Response Rate to HBV Vaccination Compared to ControlsDigestive Diseases and Sciences, 2011